• Coulton Legge

    Global Open Innovation
    Bayer

19+ years in Healthcare – Pharmaceutical and Consumer (OTC / FMCG)

Physicist driven by innovation to generate commercial value (backed by intellectual property where possible), using consumer insights for new product development and investigating new technologies for unmet consumer health needs.

Current Categories of interest:
Analgesics, Allergy, Cough and Cold, Dermatology, GI, Nutritionals, Sun Care and Foot Care

Experience in building teams with multidisciplinary skills, both in UK and US and working with 3rd parties.



  • Edwin Bessant

    CEO
    Ceuta Healthcare

Edwin is the Group CEO of the Ceuta Group & was the joint & lead founder of Ceuta Healthcare, founded 23 years ago & now established as a leading & multi-award winning consumer outsourcing organisation , with an enviable client base which includes: Procter & Gamble, Pfizer Consumer, Boehringer, J&J, Sanofi, Prestige, Combe, Beirsdorf & Unilever & has a  Global reach to over 107 International markets through the Ceuta International Alliance network.

Edwin has acquired  a number of other added value businesses  within the Group through its Integrated Platform of services,  these include advisory, [CCG]  sales, consumer/ trade marketing, strategy, logistics  [Ceuta Healthcare, Brandshapers & Go2Grocery],    brand strategy creative design [ 1HQ],      shopper data insights, category management, [Bridgethorne] & [Collidascope]    adaptive artwork solutions [Impackt],   and field/experiential marketing [ Orchid,Atomic, PromoSaphiens & EuroPromotions]].

Edwins career has been associated with Blue chip corporations: Cadburys / Wilkinson Sword & Pfizer Consumer.
Edwin as a Director was placed on A European Fast Track programme with Wyeth / Pfizer Consumer – Trade Marketing / Market Strategist & Analyst.

Edwin has been recognized for leading & building a Vision for the Ceuta Group he has received an accolade of awards which include: International Finance awards – 2015 Global 100 Leadership Awards for building out & leading a Vision [ other CEO recipients included Apple, Facebook, Disney, Microsoft, Uber, LVMH, etc] , Deloittes Director of the Year, Who’s Who of Business Leaders
Edwin is a Fellow of the Princes Enterprise Trust, a Regional Fellow of the Royal Society of Medicine & Fellow of the Institute of Directors.

Edwin is currently focused on building out a Global acquisition strategy & leading the organisation, currently they have 12 companies within the Group and a further 5 acquisitions in the pipeline.
Ceuta has two USA investors who collectively own 60% of the business – Juggernaut Capital – Washington DC & Advantage Solutions – Irvine California
www.ceutahealthcare.com
www.ceutagroup.com



  • Brian Buchert

    Vice President, Corporate Strategy and M&A
    Church & Dwight

Brian is the Vice Presdient of Corporate Strategy and M&A for Church & Dwight based out of Ewing, NJ – Church & Dwight is a manufacturer of consumer and chemical products and owns such iconic brands as Arm & Hammer, Trojan, OxiClean, First Response, Spinbrush, Nair and Orajel with total sales of $3.4 billion and a market capitalization of $11 billion. Since joining Church & Dwight the company has acquired Toppik hair care, Vi-Cor Animal Nutrition, RepHresh and Replens Women’s health brands, Avid Health (L’il Critters and VitaFusion gummy vitamins), OxiClean, Orajel, Simply Saline, Batiste, Toothtunes and Feline Pine brands and sold five businesses. Brian joined Church & Dwight in 2006 after a 13 year career on Wall Street, in Private Equity and Corporate M&A. Brian began his career working in the Investment Banking Group at Morgan Stanley. Brian then went on to work in Private Equity at Columbia Capital in Washington, DC making over 20 direct investments totaling over $400 million in early stage Technology and Telecommunications companies. Most recently prior to Church & Dwight he headed the M&A department at Lafarge North America which was the largest U.S. basic materials provider before being acquired in 2006. He received his BS in Finance from Georgetown University.



  • Barry Clare

    Partner
    Clarat Partners

Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry sector. He has held a number of top roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare, retail consumer products and financial services.

Barry created Boots Healthcare International, the international ‘over the counter’consumer healthcare business of the Boots Company PLC; through Barry’s leadership the business became the fastest growing ‘over the counter company’in Europe. During his time as a board member of Boots, Barry was responsible for the global expansion of international brands including Nurofen, Strepsils and Clearasil. Following his career at Boots, Barry has been Chairman of a number of successful, pioneering healthcare companies that have brought several ground breaking innovations to the NHS. Barry’s portfolio of innovative healthcare solutions include: e-health business, diagnostics tests and medicines development.



  • Brian Russell

    CEO
    Contempolab

Brian has 25 years experience in Global Commercialisation, Venture Financing and Innovation. CEO, Founder of Zephyr Technology Corp ( Acquired by Covidien COV: NYSE in 2014), a global leader in wearable sensors . 11 years experience in Start Up and financing with Venture Capital and strategic investors. Strategic partner co development and commercialisation strategic negotiations. Subject matter expert in wearable and remote physiological monitoring including FDA cleared and consumer. Brian combines technology and business to drive business growth. Experience includes. NCSU Nanotech Advisory board, Corporate Development at Medtronic. CEO/Founder at Zephyr. Business Development and Chip Designer at Analog Devices. Analog Telecommunications designer for Nokia, Cambridge, UK. Consumer Electronics product designer at Fisher and Paykel, NZ. Bachelor of Electrical and Electronic Engineering from Auckland University, New Zealand. Patents in optics, Silicon Chips, control systems, wearable sensors , physiological algorithms and wireless solutions. Other activities include testifying to Congress on behalf of NASA, Dept of Homeland Security advisor on physiological monitoring. Advising various NZ companies on market entry to North American markets.



  • Jeremy Kelly

    Director
    Deal-Flow

Jeremy is a Director and co-founder of Deal Flow a specialist International Consumer Health BD Consultancy and Brokerage Company based in UK. Jeremy has over 30 years’ experience in Consumer Health. He started his career in sales marketing with L’Oreal Reckitt and Wellcome, working across all major categories as well as launching number of key switch brands including Zovirax, before taking up the role of European BD Director with Warner Lambert. In 1996 he started his original business Evidence Based Marketing and over the last 20 years has consulted to all of the major OTC corporations in M&A, Licensing and Strategic Planning across all major therapeutic categories. In 2016 Jeremy started his latest venture Deal Flow, a targeted database BD networking and brokerage service, which specializes in screening and connecting buy and sell side opportunities internationally, across the full spectrum of Consumer Health business models in OTC Wellness Nutritionals Herbals and Digital.



  • Andrea Ponti

    Executive Partner and Founder
    GHO Capital

Andrea has 30 years of investment banking experience, focusing on healthcare since 1996. He created both JP Morgan’s and Goldman Sachs’ European investment banking healthcare franchises, advising on some of the most significant Mergers and Acquisitions for leading pharmaceutical, medical device and hospital companies but also advising emerging companies and private equity on M&A and debt or equity financing. Over the last five years he was Vice Chairman of European Investment Banking and Global co-head of Healthcare at J.P. Morgan. Prior to that Andrea was at Goldman Sachs, where he was Partner, Managing Director, Head of European Healthcare, Consumer and Retail and also Co Global Head of Healthcare and covered a variety of roles during his time at the firm including member of the firm-wide Commitments Committee. Andrea sits on the board of Cell Medica and holds a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill, where he is also a member of the Arts and Sciences Foundation Board of Directors



  • Eric Desai

    Principal
    Greenhouse Capital Partners

Eric is an experienced growth equity and venture capital investor, with a background in consumer products and services. Prior to joining Greenhouse, Eric was a Vice President at Robin Lane Capital, a consumer goods and services growth equity investment firm. Eric has also held Corporate Strategy and Product Development roles at Revolution Foods and Philips, focusing on Food, Consumer Lifestyle and Healthcare. Eric spent his early career in the M&A Group at PricewaterhouseCoopers in the Netherlands.

Eric holds a BS in Finance and Accounting from the University of Arizona, and an MBA from UC Berkeley’s Haas School of Business.

 



  • Chris Harley-Martin

    VP & Global Head, GSK Consumer Healthcare Business Development
    GSK Consumer Healthcare

Experienced Global Strategy & Corporate Development professional and adviser to early stage ventures



  • William Hood

    Managing Director
    Houlihan Lokey

Mr. Hood is a Managing Director at Houlihan Lokey and leads the firm’s consumer health and wellness practice. He is well known as a leading mergers and acquisitions (“M&A”) advisor to the to the consumer health industry having led many well-known and notable transactions.

Mr. Hood’s selected recent consumer health and wellness transactions include the sale of Iovate to Xiwang Foods in China, the sale of Perrigo’s VMS business to IVC, the sale of Captek Softgel International to Swander Pace Capital; the purchase of FoodState Inc. by Pharmavite LLC, a wholly owned subsidiary of Otsuka Pharmaceutical Co.; the purchase of C.B. Fleet Co. by Gryphon Investors; the sale of FDC Vitamins (Nutri-Force Nutrition) to Vitamin Shoppe, Inc.; the sale of Cornerstone Research & Development, Inc. to Integrity Nutraceuticals (H.I.G. Capital, LLC); the sale of Healthy Directions LLC to Helen of Troy Ltd.; the sale of Advanced Beauty, Inc.’s Dr. Teal’s brand to Parfums de Coeur, Ltd. (Yellow Wood Partners, LLC); the sale of Jamieson Laboratories to CCMP Capital; the sale of Santa Cruz Nutritionals to RoundTable Healthcare Partners; the sale of Schiff Nutrition International, Inc. to Reckitt Benckiser Group PLC; the growth equity financing of Beachbody provided by LNK Partners; the sale of Avid Health, Inc. to Church & Dwight Co., Inc.; the purchase of Airborne by Schiff Nutrition International, Inc.; the PIPE offering for Vitacost.com, Inc. (NASDAQ: VITC); and the sale of Alacer Corp. (Emergen-C) to Pfizer Inc.

Prior to joining Houlihan Lokey, Mr. Hood spent nine years at Sawaya Segalas, a consumer products–focused boutique firm, where he was a Director and Partner, originating and executing M&A transactions.

Mr. Hood began his career at PaineWebber, where he executed M&A, equity, and debt transactions.

Mr. Hood grew up in the U.K. and Hong Kong and holds a B.S. from Georgetown University.



  • Rajesh Mishra

    Vice President R&D Consumer OTC
    Johnson & Johnson

Rajesh (Raj) Mishra M.D., PhD, currently serves as Vice President R&D Consumer OTC and Head of OTC R&D for the EMEA region based out of the UK. Raj has a wealth of U.S. and global industry experience with broad experience in OTC medicines across multiple therapeutic categories. Raj joined Johnson & Johnson Family of Consumer Companies as Vice President Medical and Clinical Affairs, Global OTC in March, 2014. In this role Raj served on the McNeil Management Board, and also on the Global OTC leadership team. Raj was responsible for providing medical and clinical oversight across the entire range of OTC therapeutic areas including pain, upper respiratory/allergy, digestive health, smoking cessation, and RX to OTC switch.

Prior to his current role at Johnson & Johnson, Raj was Vice President and Global Head Medical Affairs & Clinical Research at Merck Consumer Care. At Merck, Raj led the Global Medical and Consumer Science Innovation Center of Excellence, and had responsibility for Medical Affairs, Clinical Operations and the Consumer Science Research Center, providing strategic direction, operational, medical/clinical leadership and management for multiple franchises. Before joining Merck, Raj spent 5+ years in various roles within Medical Affairs and R&D product development at GlaxoSmithKline serving as Vice President R&D for Weight Control and Smoking Cessation and Head of Medical Affairs North America.

Raj earned his Doctor of Medicine (MD) and Masters in General Surgery (MS) at B.J. Medical College, Pune University in India. Raj also holds a Doctor of Philosophy (PhD) In Pharmacology from Southern Illinois University Carbondale School of Medicine and an Advanced Management Program Certification from Wharton, University of Pennsylvania.



  • Peter C. Mann

    Operating Partner
    Juggernaut Capital Partners

Mr. Mann has an extensive consumer products background, both in managing and investing in growth businesses, primarily in the Over-The-Counter Drug (OTC) and Personal Care industries. Currently, he is an Operating Partner at Juggernaut Capital Partner, a mid-sized private equity firm primarily investing in consumer product and service companies. In this capacity, Mr. Mann identifies and evaluates investment opportunities and then serves as both an advisor and Board member of portfolio companies. In 2010, Mr. Mann co-founded Yellow Wood Partners, a private equity group also focused on the Consumer Packaged Goods industries. During that period, he also served as CEO of Bedrock Brands, an OTC portfolio company of Yellow Wood.

Previously, Mr. Mann co-founded Blacksmith Brands, Inc in April of 2009 and became the Company’s Chairman and CEO. In this role, he led the creation of the Company’s sales, marketing and operations capabilities as they transitioned a group of “orphan” brands into a successful stand-alone company which was later sold to Prestige Brands producing an attractive financial return to its investors. Mr. Mann was also the Founder, Chairman and CEO of Prestige Brands Holdings, Inc. Mr. Mann was instrumental in building Prestige Brands starting with the initial acquisition of a small portfolio of OTC and Household brands in 2001, acquiring numerous additional brands and ultimately culminating with a successful initial public offering on the New York Stock Exchange (NYSE: PBH) in 2005. During his seven years at Prestige, Mr. Mann delivered strong financial gains for two different private equity owners. Prior to joining Prestige Brands, Mr. Mann worked the majority of his career at Block Drug Company where he served in various roles, eventually becoming a Member of the Office of Chief Executive and President of the Americas Division. Mr. Mann received an A.B. from Brown University, and he currently resides in the Hudson River Valley.



  • Stephen Sands

    Vice Chairman Investment Banking, Chairman Global Healthcare Group
    Lazard

Stephen Sands is Vice Chairman of U.S. Investment Banking and Chairman Global Healthcare Group at Lazard. He also sits on the board of Lazard Capital Markets. Sands has advised some of the largest pharmaceutical and biotechnology transactions, including Pfizer’s acquisition of Pharmacia and Warner Lambert and Hoechst on the formation of Aventis. Prior to Lazard, Sands was a partner in the health-care practice of McKinsey & Company, and he co-founded two companies, Enzytech and Opta Foods. Before their sales, Sands was a director of National Imaging Associates (Magellan) and Isogen (Monsanto). A member of the Brookings/Gates Global Heath Innovative Financing Advisory Group, Sands was named The Cures Start Here Business Leader of the Year in 2008 by the New York Biotechnology Association. Sands received a B.A. from Oberlin College, a B.S. and M.S. in chemical engineering from Washington University in St. Louis, and an M.B.A. in finance from New York University.



  • Alexander Hoffman

    Principal
    Merck Ventures

Alexander Hoffmann joined the New Businesses team as Principal in October 2016. Previously, Alexander was the Head of Digitization Africa, leading the Digital Strategy for Africa at Merck. Based out of Nairobi, Kenya, he was instrumental for the launch and management of several digital health solutions supporting the existing businesses of Merck across the continent. He was also the main driver of the Merck Africa Accelerator program, looking after digital health startups in this region. Prior to that, Alexander has held various positions at several internet startups, ranging from Skrill and SumUp (online and mobile payments) to consumer-focused online businesses at Rocket Internet. Alexander holds a Master’s degree in Marketing from Kingston Business School, UK. Alexander is based in Amsterdam.



  • Siddhart Nahata

    Managing Director, Healthcare Investment Banking
    Morgan Stanley

15 years Investment Banking / 11 years at Morgan Stanley
• Joined Morgan Stanley’s Investment Banking Group in London in 2005 after spending 4 years at JPMorgan
• Worked in London, New York and Mumbai focused on biopharmaceuticals (Large Cap, Specialty and Generics) and OTC
• Graduate degree in Accounting and Finance from the University of Warwick and a post-graduate degree in Accounting and Finance from the London School of Economics

Deal Experience:
–KKRs acquisition of LGC–Sale of Roxane Laboratories to Hikma plc ($2.65Bn)
–Spin-off of Indivior from Reckitt Benckiser plc
–Sale of Omega Pharma to Perrigo (EUR 3.6Bn)
–AstraZeneca’s defence against Pfizer (~$120Bn)
–Mylan’s acquisition of Agila Specialties ($1.6Bn)–Cipla’s acquisition of Cipla Medpro South Africa ($550MM)
–Reckitt / Bristol-Myers Squibb LatAm OTC
–Pronova’s sale to BASF (NOK 5.0Bn)–Reckitt’s acquisition of Schiff Nutrition ($1.4Bn)
–AstraZeneca’s acquisition of Ardea Biosciences ($1.3Bn)
–Sale of Paras Personal Care brands by Reckitt Benckiser to Marico
–Altor’s acquisition of Orchid Orthopaedics–Sale of Paras Pharma to Reckitt Benckiser ($725MM)
–Parkway Holdings / Khazanah ($3.7Bn)
–Acquisition of Orchid Injectables by Hospira ($400MM)
-Acquisition of Piramal Healthcare by Abbott ($3.7Bn)
–Sale of Cambridge Antibody Technologies to AstraZeneca (£702MM)
–Fresenius’ acquisition of Dabur Pharma ($365MM)–Bausch & Lomb’s sale to Warburg Pincus ($4.6Bn)
–Nycomed’s acquisition of Bradley Pharmaceuticals ($346MM)
–Shire’s acquisition of New River Pharmaceuticals ($2.6Bn)
–Nycomed’s acquisition of Altana Pharma (EUR 4.2Bn)
–Sale of Cambridge Antibody Technology to AstraZeneca (GBP 702MM)
–Sale of Medi-Partenaires to Investor Group (EUR 323MM)
–IPO of Grifols, LifeCycle Pharma
–Exchangeable Bond Offering for the Govt. of Hungary
–Financings for AstraZeneca, GSK, Mylan, AstraZeneca, Shire, Nycomed, Bristol Myers and Schering-Plough



  • Kevin Foley

    Vice President Worldwide Business Development
    Pfizer Consumer Healthcare



  • Andy Tisman

    Global Senior Principal Consumer Health
    Quintiles IMS

Andy Tisman is Global Senior Principal, Consumer Health at QuintilesIMS, responsible for leading QI Consumer Health Consulting and Services globally. Andy joined QI in 2005 with a strong industry and consulting background

Profile overview:
  • Over 15 years consulting experience across both OTC/CHC and pharma
  • Andy has successfully led many strategic consulting and operational projects in most major geographies.
  • Leads QuintilesIMS Consumer Health C&S and global Consumer Health Consulting & Services Community
  • Andy also has extensive OTC/CHC & pharma marketing/marketing management experience from over 15 years with SmithKline Beecham in local and international (pan-European and global) roles
  • Andy speaks regularly at industry events and publishes extensively on CHC and OTC issues
Areas of expertise:
  • Strategy development, including global, regional & local strategy
  • Commercial Effectiveness, Go-to-Market & Commercial Models
  • Market entry/brand launch
  • Rx/OTC Switch
Relevant experience: Andy works extensively on OTC strategy projects globally, with experience in both developed and emerging geographies and has special interest in evolving trends and implications on market evolution


  • Andrew van der Vord

    Vice-Chairman, Co-Head Consumer Retail Investment Banking
    RBC

  • Andrew van der Vord is the Vice Chairman and Co-Head in the Consumer Retail group within the Investment Banking Division at RBC, based in New York
  • Mr. van der Vord joined RBC from Credit Suisse, where he was Global Vice Chairman of Consumer and Retail Investment Banking. Prior to joining Credit Suisse in 2009, he was Global Head of Consumer and Retail Investment Banking at J.P. Morgan, covering a variety of food and beverage, tobacco, household and personal care companies. Prior to joining JP Morgan in 2006, he was Global Head of Consumer Investment Banking at Citigroup and has been covering consumer companies since the beginning of his investment banking career at Schroders in 1990
  • Mr. van der Vord has been involved in a number of industry-defining transactions, including Altria’s acquisition of UST, Inbev’s hostile takeover of Anheuser-Busch, the IPO of Sealy Mattress, WhiteWave and Pinnacle Foods, Kellogg’s acquisition of Keebler, the IPO of Kraft Foods, the sale of Bavaria to SABMiller, the sale of Bestfoods to Unilever, the successful defense of Ralcorp against ConAgra, and a variety of transactions for Constellation Brands, Cott, Kellogg, Energizer, Kraft, Smithfield Foods, Philip Morris International, Imperial Tobacco, Ralcorp, Post Foods, JBS Friboi, KKR, GTCR, Bain, Blackstone, Apollo, and Fortune Brands, among others. He has closed over 300 transactions with a total value in excess of US$500 billion thus far in his career as a Consumer banker
  • Mr. van der Vord holds a B.A. (Hons) from Durham University. He is a qualified accountant (ACA) and a qualified treasurer (MCT)


  • Divya Shah

    Sr. Director, Product, Digital Health at Samsung Strategy and Innovation Center
    Samsung

Leadership, Vision & Strategic direction, Managing large scale projects, Collaborating with large size engineering teams across the globe and driving towards concrete deliverables, User empathy, Indepth user interface design experience and passion for building consumer, social products.



  • Marc Rovner

    General Manager, Consumer Healthcare
    Sanofi

My career has spanned a wide range of consumer products and services, with responsibilities for both domestic and international businesses. My time as a line manager has been at both Fortune 100 companies like International Paper, Unilever, and Pfizer, as well as entrepreneurial ventures such as Reckitt-Benckiser, Renaissance Cosmetics and SmartAnalyst. In these roles, I created the strategies, built the teams and executed the plans that delivered commercial and financial successes.

My marketing and communication accomplishments have included:
– Creating the first kraft paper consumer cooler bag for International Paper,
– Launching Surf detergent in the US and building Lux soap in Japan for Unilever,
– Defending Finish against P&G’s Fairy detergent for Reckitt-Benckiser in the UK,
– Giving a manicure to the Wal-Mart cosmetics buyer for Renaissance Cosmetics,
– Freshening every mouth in America with Listerine PocketPaks for Pfizer,
– Developing cogent business life science strategies for clients of SmartAnalyst.
– Launching Dulcolax for Women.

Currently, I am the General Manager for Boehringer-Ingelheim’s US Consumer Healthcare business.

Previously, I was the Managing Director of SmartAnalyst, a strategic research company backed by two leading venture capital firms, In this role, I tripled revenues by building strong relationships and delivering strategic consulting projects to such clients as J&J, PepsiCo, Coca-Cola, Unilever, Pfizer, BMS, Novartis and Church & Dwight.

I have a BA with honors from the University of Pennsylvania and a MA from the University of Chicago, where I was a Noyes Fellow. I live with my wonderful wife and three great children in White Plains, NY. I know that education doesn’t stop at school, so, beside global work and living experiences, I maintain an intimidating reading list, ponder on how to catch more bass and have leadership roles with the American Diabetes Association and Save the Children.

Specialties: Turning information into insights and creating innovations from those insights into successful initiatives. Brand positioning, consulting, successful marketing plans, strategic planning, acquisitions, advertising, working capital improvements.



  • Maayke Fluitman

    Managing Partner SelfCareFactorY; owner care2create
    SelfCareFactorY

Maayke received her Master in Pharmacy from the Department of Pharmaceutical Sciences at the University of Utrecht, Netherlands. She has an extensive experience in pharmacy, primary care and self care. After gaining four years’ experience working as a community pharmacist she worked for over 10 years for Alliance Healthcare, where, in her final role as Pharmacy Governance Manager she was responsible for Clinical Governance Program of the pharmacy chain. In 2008 she joined the board of the Royal Dutch Association of Pharmacists (KNMP), of which she was vice-president for four years. She currently is president of the Department of Pharmacists, Medicine & Society at the KNMP.

She started her own business, care2create, to be able to create and launch new concepts in healthcare, wellness and self care. Maayke is also associate partner of Altuïtion, a marketing research company specialised in customer journeys and engagement engineering

Her interest and experience in self care led to strategic involvement on policy level, European as well as International, on creating standards and strategy to develop self care further.
Together with Jan Smits, she owns the SelfCareFactorY, an independent platform on trends and solutions in self care. The aim of this platform is to share best practice in self care and to facilitate the exchange of ideas and to sharpen opinions

 



  • Polina Hanin

    Academy Director
    StartUp Health

Polina is the Academy Director of StartUp Health and an extremely passionate advocate for health entrepreneurs. In her role, she leads StartUp Health’s lifetime program designed to help entrepreneurs succeed at every stage of their business and attract team members, customers and capital.

Prior to joining StartUp Health in 2012, Polina was at Viscogliosi Bros., a merchant bank focused on the orthopedic industry, where she held multiple interim roles within the firm’s portfolio companies. At Centinel Spine, her responsibilities included leading M&A deals, corporate development and distribution-related operations. She also launched Musculoskeletal Clinical and Regulatory Advisers, where she focused on client relations, marketing and corporate finance.

Polina received her B.A. from Wesleyan University and an M.B.A. from the University of Chicago Booth School of Business. Follow her on Twitter @polinahanin.



  • Terri Goldstein

    Founder & CEO
    The Goldstein Group

Terri Goldstein is the Founder & CEO of The Goldstein Group. During her 25-year career, executives in the CPG and Pharmaceutical industries have turned to Terri for her expertise in brand identity and design. Terri has strengthened the brand identity and business health of over 400 global and domestic consumer products and services developing iconic brand identities that truly endure the test of time. 
 
Terri has been profiled in Advertising Age (Packaging Guru Proves What’s On Outside Counts – And Sells) and was named a GDUSA Person to Watch. She is a keynote speaker at PIMS, The Marketing Institute, CHPA and many industry conferences. She serves as a guest lecturer at FIT, regularly contributes to Adweek, Brand Packaging and Graphic Design USA, and is the author of breakthrough research on consumer behavior, recall, and sensory motivation in the retail environment. 



  • Clive Allison

    Innovation Director
    Unilever

Dr Clive Allison is Global Director of Open Innovation at Unilever one of the world’s most successful consumer goods companies. Around 200 million times a day, someone somewhere chooses a Unilever product across our Home Care, Personal Care, Foods and Refreshment product categories. At Unilever our purpose is to make sustainable living commonplace and through Open Innovation we give people and organisations the confidence to build the transformational winning partnerships required to deliver to that purpose.

Clive holds a PhD from the University of Cambridge and has more than 20 years of experience in leadership roles in R&D and Innovation across the Home and Personal Care product categories. Clive has a passion for disruptive innovation that makes a real difference in the World and in that context he leads the establishment of transformational innovation partnerships connecting Corporate, SME, Academic and Public partners to deliver business and societal impact.



  • Paul Valdez

    Founder
    Valdez Consulting Limited

Paul has been in the consumer healthcare sector for over 30 years. He has worked at a number of leading multi-nationals such as GlaxoSmithKline (GSK), Bristol-Myers Squibb and Reckitt. Senior roles in those organisations included multi-country General Management, Global Strategy and Business Development Director for Europe.

In 2011 Paul founded Valdez Consulting Limited, an international marketing and business development consultancy. The company works through a strong network of associates around Europe, helping clients to grow through geographic expansion and business development initiatives. Paul has frequently worked as an advisor for external companies wishing to enter or expand their activities in Europe, helping to locate opportunities and navigate the complexities of the region.